Evidence map›Paper›PMID 37865160›Full record

ArticleCancer letters2023

Pancreatic Ubap2 deletion regulates glucose tolerance, inflammation, and protection from cerulein-induced pancreatitis.

Ram Vinod Roy, Nicolas Means, Geeta Rao, Sima Asfa, Venkateshwar Madka, Anindya Dey, Yushan Zhang, Monalisa Choudhury, Kar-Ming Fung, Danny N Dhanasekaran and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Ram Vinod RoyPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Nicolas MeansPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Geeta RaoPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Sima AsfaPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Venkateshwar MadkaCenter for Cancer Prevention and Drug Development, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Anindya DeyPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Yushan ZhangPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Monalisa ChoudhuryPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Kar-Ming FungDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Danny N DhanasekaranPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Cell Biology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Jacob E FriedmanHarold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Howard C CrawfordDepartment of Surgery, Henry Ford Pancreatic Cancer Center, Henry Ford Health System, Detroit, MI, USA.
Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Resham BhattacharyaPeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Priyabrata MukherjeePeggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: Priyabrata-Mukherjee@ouhsc.edu.
University of Oklahoma Health Sciences Center · USHenry Ford Health System · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI James F Papin · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HANNAFON, BETHANY · 2012 to 2022
$21.3M
Molecular Mechanism of Antiangiogenic Properties of Gold NanoparticleR01CA136494 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2009 to 2020
$2.9M
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery systemR01CA253391 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2021 to 2025
$1.7M
Reprogramming Tumor Microenvironment by NanoparticleR01CA213278 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2017 to 2021
$1.7M
UBAP2, A New Molecule in Pancreatic Cancer ProgressionR01CA220237 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUKHERJEE, PRIYABRATA · 2018 to 2022
$1.6M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA136494NCI NIH HHS R01 CA213278NCI NIH HHS R01 CA220237NCI NIH HHS R01 CA253391NCI NIH HHS R01 CA260449NIGMS NIH HHS P20 GM103639
6 · The paper itself

Abstract

Ubiquitin-binding associated protein 2 (UBAP2) is reported to promote macropinocytosis and pancreatic adenocarcinoma (PDAC) growth, however, its role in normal pancreatic function remains unknown. We addressed this knowledge gap by generating UBAP2 knockout (U2KO) mice under a pancreas-specific Cre recombinase (Pdx1-Cre). Pancreatic architecture remained intact in U2KO animals, but they demonstrated slight glucose intolerance compared to controls. Upon cerulein challenge to induce pancreatitis, U2KO animals had reduced levels of several pancreatitis-relevant cytokines, amylase and lipase in the serum, reduced tissue damage, and lessened neutrophil infiltration into the pancreatic tissue. Mechanistically, cerulein-challenged U2KO animals revealed reduced NF-κB activation compared to controls. In vitro promoter binding studies confirmed the reduction of NF-κB binding to its target molecules supporting UBAP2 as a new regulator of inflammation in pancreatitis and may be exploited as a therapeutic target in future to inhibit pancreatitis.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaPancreatic NeoplasmsPancreatitisAcute DiseaseAnimalsCeruletideGlucoseInflammationMiceNF-kappa BPancreasAdaptor Proteins, Signal TransducingCeruletideGlucoseNF-kappa BUbap2 protein, mouseGlucose intolerancePancreatic ductal adenocarcinomaPancreatitisUBAP2

Identifiers

PMID37865160
PMCPMC10897936
OpenAlexW4387784261

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.